BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 11/06/25
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business UpdatesBusiness Wire • 11/06/25
BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6Business Wire • 10/22/25
BeOne Medicines: Sonrotoclax Could Set Next Stage Of Growth For Hematology PipelineSeeking Alpha • 10/14/25
BeOne Medicines' Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDABusiness Wire • 10/13/25
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive OrderInvestors Business Daily • 09/10/25
BeOne Medicines AG (ONC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/08/25
BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma PatientsBenzinga • 08/29/25
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)Business Wire • 08/29/25
European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025Business Wire • 08/27/25
BeOne Medicines: Brukinsa's Leadership And Royalty Sale Signal A Stronger FutureSeeking Alpha • 08/26/25
BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare ConferenceBusiness Wire • 08/26/25
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 MillionBusiness Wire • 08/25/25
European Commission Approves Tablet Formulation of BeOne Medicines' BRUKINSA® for All Approved IndicationsBusiness Wire • 08/21/25
This Medical Stock With Blockbuster Cancer Drug Clears Entry Amid 923% Earnings GrowthInvestors Business Daily • 08/15/25
BeOne Medicines Ltd. - Sponsored ADR (ONC) Reports Q2 Earnings: What Key Metrics Have to SayZacks Investment Research • 08/06/25
BeOne Medicines Announces Second Quarter 2025 Financial Results and Business UpdatesBusiness Wire • 08/06/25
BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom's MacroglobulinemiaBusiness Wire • 07/31/25
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC TreatmentBusiness Wire • 07/28/25
The S&P 500 and Nasdaq Are Joined By These Stocks Hitting New HighsInvestors Business Daily • 07/18/25
BeOne Medicines Ltd. - Sponsored ADR (ONC) Surges 4.0%: Is This an Indication of Further Gains?Zacks Investment Research • 07/18/25